BR9808441A - Composição farmacêutica para administração a um animal, vetor transportador, vetores para transportar e expressar genes selecionados em escherichia coli e de uma cepa de mycobacterium, processo para administrar a um animal uma quantidade eficaz da composição farmacêutica, e, meio de cultura. - Google Patents

Composição farmacêutica para administração a um animal, vetor transportador, vetores para transportar e expressar genes selecionados em escherichia coli e de uma cepa de mycobacterium, processo para administrar a um animal uma quantidade eficaz da composição farmacêutica, e, meio de cultura.

Info

Publication number
BR9808441A
BR9808441A BR9808441-0A BR9808441A BR9808441A BR 9808441 A BR9808441 A BR 9808441A BR 9808441 A BR9808441 A BR 9808441A BR 9808441 A BR9808441 A BR 9808441A
Authority
BR
Brazil
Prior art keywords
animal
pharmaceutical composition
mycobacterium
vectors
administering
Prior art date
Application number
BR9808441-0A
Other languages
English (en)
Portuguese (pt)
Inventor
Abdel Hakim Labidi
Original Assignee
Cytoclonal Pharmaceutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cytoclonal Pharmaceutics Inc filed Critical Cytoclonal Pharmaceutics Inc
Publication of BR9808441A publication Critical patent/BR9808441A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/74—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/04—Mycobacterium, e.g. Mycobacterium tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/522—Bacterial cells; Fungal cells; Protozoal cells avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/523—Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Biochemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
BR9808441-0A 1997-03-28 1998-03-27 Composição farmacêutica para administração a um animal, vetor transportador, vetores para transportar e expressar genes selecionados em escherichia coli e de uma cepa de mycobacterium, processo para administrar a um animal uma quantidade eficaz da composição farmacêutica, e, meio de cultura. BR9808441A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US4284997P 1997-03-28 1997-03-28
PCT/US1998/006056 WO1998044096A2 (fr) 1997-03-28 1998-03-27 Vaccins recombines a base de mycobacteries

Publications (1)

Publication Number Publication Date
BR9808441A true BR9808441A (pt) 2000-05-23

Family

ID=21924071

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9808441-0A BR9808441A (pt) 1997-03-28 1998-03-27 Composição farmacêutica para administração a um animal, vetor transportador, vetores para transportar e expressar genes selecionados em escherichia coli e de uma cepa de mycobacterium, processo para administrar a um animal uma quantidade eficaz da composição farmacêutica, e, meio de cultura.

Country Status (6)

Country Link
EP (1) EP0973881A2 (fr)
JP (1) JP2001518781A (fr)
AU (1) AU6780498A (fr)
BR (1) BR9808441A (fr)
CA (1) CA2284736A1 (fr)
WO (1) WO1998044096A2 (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1272213B1 (fr) * 2000-04-06 2006-03-08 SEER Pharmaceuticals, LLC. Systeme d'administration microbienne
US20040076639A1 (en) 2001-02-20 2004-04-22 Yasuhiro Yasutomi Novel medicinal use of alpha antigen or alpha antigen gene
WO2003006035A1 (fr) * 2001-07-10 2003-01-23 Stanford Rook Limited Compositions antivomitives
WO2013039069A1 (fr) 2011-09-13 2013-03-21 日本ビーシージー製造株式会社 Nouveau vaccin renfermant bcg recombinant
CN108285881B (zh) * 2018-01-04 2021-06-08 广州大学 一种具有同步产电和反硝化活性的分支杆菌及其应用
AU2019221709B2 (en) 2018-02-19 2024-04-18 Biofabri S.L. Compositions for use as a prophylactic agent to those at risk of infection of tuberculosis, or as secondary agents for treating infected tuberculosis patients

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5807723A (en) * 1987-03-02 1998-09-15 Whitehead Institute For Biomedical Research Homologously recombinant slow growing mycobacteria and uses therefor
CA2045842A1 (fr) * 1990-07-16 1992-01-17 William R. Jacobs Adn capable de s'integrer dans un site particulier de mycobacteries
AU660430B2 (en) * 1990-11-08 1995-06-29 Stanford Rook Limited Mycobacterium as adjuvant for antigens
AU681572B2 (en) * 1991-10-21 1997-09-04 Med Immune, Inc. Bacterial expression vectors containing DNA encoding secretion signals of lipoproteins

Also Published As

Publication number Publication date
CA2284736A1 (fr) 1998-10-08
EP0973881A2 (fr) 2000-01-26
WO1998044096A2 (fr) 1998-10-08
WO1998044096A3 (fr) 1999-01-14
JP2001518781A (ja) 2001-10-16
AU6780498A (en) 1998-10-22

Similar Documents

Publication Publication Date Title
Jalava et al. Bacterial ghosts as vaccine candidates for veterinary applications
Ou et al. Genetic engineering of probiotic Escherichia coli Nissle 1917 for clinical application
Kong et al. Regulated programmed lysis of recombinant Salmonella in host tissues to release protective antigens and confer biological containment
Jones et al. Poly (DL-lactide-co-glycolide)-encapsulated plasmid DNA elicits systemic and mucosal antibody responses to encoded protein after oral administration
Curtiss et al. Selective delivery of antigens by recombinant bacteria
ES2192555T3 (es) Vectores basales del virus 2 adenoasociado.
Waine et al. Nucleic acids: vaccines of the future
CN1902317B (zh) 质粒保持
Shiau et al. Prothymosin α enhances protective immune responses induced by oral DNA vaccination against pseudorabies delivered by Salmonella choleraesuis
JP4435870B2 (ja) マイコバクテリア感染症に対するワクチン
BR9808441A (pt) Composição farmacêutica para administração a um animal, vetor transportador, vetores para transportar e expressar genes selecionados em escherichia coli e de uma cepa de mycobacterium, processo para administrar a um animal uma quantidade eficaz da composição farmacêutica, e, meio de cultura.
Loeffler et al. Comparison of different live vaccine strategies in vivo for delivery of protein antigen or antigen-encoding DNA and mRNA by virulence-attenuated Listeria monocytogenes
Ding et al. Attenuated Listeria monocytogenes protecting zebrafish (Danio rerio) against Vibrio species challenge
Fry et al. Gene gun DNA immunization of cattle induces humoral and CD4 T-cell-mediated immune responses against the Theileria parva polymorphic immunodominant molecule
CN102335421A (zh) 一种减毒沙门氏菌诱导型分泌表达口服疫苗递呈系统及其应用
U'ren et al. Vaccination with liposome–DNA complexes elicits enhanced antitumor immunity
Atkins et al. Recombinant Salmonella vaccines for biodefence
JPS60120822A (ja) 免疫原性調製物
Yin et al. Construction and immunogenicity of a DNA vaccine containing clumping factor A of Staphylococcus aureus and bovine IL18
Groschup et al. Modified Feist broth as a serum-free alternative for enhanced production of protective antigen of Erysipelothrix rhusiopathiae
Keane-Myers et al. Evolution of electroporated DNA vaccines
Ramalingaswami Importance of vaccines in child survival
Kim et al. Modulation of protective immunity against herpes simplex virus via mucosal genetic co-transfer of DNA vaccine with β2-adrenergic agonist
KR102259933B1 (ko) 포자 표면발현을 이용한 탄저 포자 백신의 제조방법 및 탄저 포자 백신
Wu et al. Anti-class II monoclonal antibody-targeted Vibrio cholerae TcpA pilin: modulation of serologic response, epitope specificity, and isotype

Legal Events

Date Code Title Description
B08F Application fees: dismissal - article 86 of industrial property law

Free format text: REFERENTE A 6A, 7A, 8A E 9A ANUIDADES.

B08K Lapse as no evidence of payment of the annual fee has been furnished to inpi (acc. art. 87)

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 1889 DE 20/03/2007.